Presentation is loading. Please wait.

Presentation is loading. Please wait.

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Published byGeorge Hutchinson Modified over 6 years ago

Similar presentations

Presentation on theme: "Optimizing Neoadjuvant Treatment for Primary Breast Cancer"— Presentation transcript:

1 Optimizing Neoadjuvant Treatment for Primary Breast Cancer

2

3 Agenda

4 Theoretical Rationale for Neoadjuvant Therapy in Breast Cancer

5 NSABP B-18 Neoadjuvant vs Adjuvant Doxorubicin + Cyclophosphamide (AC)

6 NSABP B-18 Disease-Free and Overall Survival Rates

7

8 NSABP B-18 Disease-Free and Overall Survival Rates According to Response

9 CREATE-X 5-Year Efficacy (N = 885)

10

11

12 The Relative Efficacy of Neoadjuvant Endocrine Therapy vs Chemotherapy

13 NeoSphere Study Design

14 NeoSphere Neoadjuvant Therapy in HER2+ BC: pCR Results

15 NeoSphere Key Safety Signals

16 TRYPHAENA Study Design

17

18 APHINITY Study Schema

19

20 Neoadjuvant Therapy for TNBC GeparSixto -- Study Design

21 GeparSixto DFS Rates by Breast Cancer Subtype

22 WSG-ADAPT TN Study Design

23 WSG-ADAPT TN pCR

24 TNBC: Clinically Targetable Pathways

25

26

27

28

29

30

31

Download ppt "Optimizing Neoadjuvant Treatment for Primary Breast Cancer"

Similar presentations

Www.OncologyEducation.ca San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.

San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Integration of Taxanes in the Management of Breast Cancer

Integration of Taxanes in the Management of Breast Cancer
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.

Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.
Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER

HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center www.cccancer.com Wichita,

Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Assistant Professor of Medicine Dana-Farber Cancer Institute

Assistant Professor of Medicine Dana-Farber Cancer Institute
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.

Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.

Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
Baselga J et al. Proc SABCS 2010;Abstract S3-3.

Baselga J et al. Proc SABCS 2010;Abstract S3-3.
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast.

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast.
Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes:

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes:
The Effect on pCR of Bevacizumab and/or Antimetabolites Added to Standard Neoadjuvant Chemotherapy: NSABP Protocol B-40 1 Neoadjuvant Bevacizumab and Anthracycline–Taxane-Based.

The Effect on pCR of Bevacizumab and/or Antimetabolites Added to Standard Neoadjuvant Chemotherapy: NSABP Protocol B-40 1 Neoadjuvant Bevacizumab and Anthracycline–Taxane-Based.

Similar presentations

Ads by Google